Grifols S.A. ADR Stock
Grifols S.A. ADR Stock
Grifols S.A. ADR took a tumble today and lost -€0.300 (-3.820%).
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | -3.820% | -5.031% | -3.822% | 10.219% | -0.658% | -10.651% | -52.540% |
| Beximco Pharmaceuticals Ltd. GDR | -34.180% | 8.333% | 6.122% | 21.495% | 16.071% | -1.887% | -49.020% |
| Eledon Pharmaceuticals Inc. | 2.350% | 20.833% | 33.846% | -54.688% | 35.938% | -44.231% | -85.403% |
| SELLAS Life Sciences Group Inc | -2.930% | 14.214% | 70.750% | 229.633% | 20.459% | 24.272% | -31.467% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat